Clinical Characteristics Of Pegaspargase-containing Chemotherapy In The Treatment Of Adult NK/T-cell Lymphoma

Objective: To retrospectively analyzed the clinical characteristics of patients receiving pegaspargase(PEG-ASP)containing chemotherapy regimens for extranodal NK/T-cell lymphoma(ENKTCL),explored the related factors affecting the prognosis and adverse drug reactions,deepened the understanding of the disease,and better served the clinic.Methods: Collected the clinical data(including age,gender,involved site of lesion,Ann Arbor stage,CA stage,treatment mode,etc.)of adult patients who were newly diagnosed with ENKTCL-and treated with PEG-ASP containing chemotherapy regimen from January 2015 to November 2022 in the First Affiliated Hospital of Wannan Medical College,analyzed.Summarized the clinical characteristics of the patients,possible factors affecting the prognosis,and adverse drug reaction grade.SPSS 25.0 statistical software was used for data processing.Results: ENKTCL patients had a male-to-female ratio of 2.22:1 and a median age of54(29 to 73).Most of the involved sites of the lesions are located in the nose,and the non-nasal region may involve the skin,gastrointestinal tract,bone,liver,lung,and adrenal gland.In patients with nasal involvement,bilateral nasal involvement was more common.Twenty-nine patients had a complete response(CR)rate of 72.4%,an overall response rate(ORR)of 79.3%,and a median follow-up time of 27.5 months.The ORR was100.0% in the non-P-GEMOX group and 62.5% in the P-GEMOX group,which was statistically different(P value = 0.02).In ENKTCL patients with Ann Arbor stage ≥ II(P = 0.042),CA stage ≥ II(P = 0.016),and PINK-E score ≥ 2(P = 0.044),the ORR in the non-P-GEMOX group was 100.0%,which was different from the ORR in the P-GEMOX group,respectively.Conclusion: ENKTCL patients are aggressive and have poor prognoses.P-GEMOX regimen is effective in patients with early or low-risk disease,and P-GEMOX combined with etoposide can be considered in patients with advanced or high-risk diseases,which helps improve patients’ prognosis.In the treatment process with PEG-ASP as the cornerstone drug,preventive protection of the liver and pancreas can be considered to improve the patient’s quality of life.